Outlook Therapeutics, Inc. (OTLK) DCF Valuation

Outlook Therapeutics, Inc. (OTLK) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Outlook Therapeutics, Inc. (OTLK) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore Outlook Therapeutics, Inc.'s (OTLK) financial potential with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate the intrinsic value of Outlook Therapeutics, Inc. (OTLK) and refine your investment approach.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -35.8 -51.5 -62.9 -57.4 -71,703,235.0 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .6 .3 .2 .0 .0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -36.3 -51.7 -63.1 -57.4 -71,703,235.0 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 12.5 14.5 17.4 23.4 14,927,538.0 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 2.4 2.2 3.5 6.6 7,968,725.0 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % -0.00371531 -0.00371531 -0.00371531 -0.00371531 -0.00371531 -0.00371531 -0.00371531 -0.00371531 -0.00371531 -0.00371531
EBITAT -33.2 -51.7 -63.1 -57.4 -71,705,899.0 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -30.3 -51.7 -61.6 -54.3 -63,737,180.6 -7,968,725.0 .0 .0 .0 .0
WACC, % 862.85 942.89 942.89 942.89 942.89 926.88 926.88 926.88 926.88 926.88
PV UFCF
SUM PV UFCF -776,013.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -776,013
Net Debt -14,629,709
Equity Value 13,853,696
Diluted Shares Outstanding, MM 18,549
Equity Value Per Share 746.88

What You Will Receive

  • Comprehensive Financial Model: Outlook Therapeutics’ actual data facilitates accurate DCF valuation.
  • Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other essential variables.
  • Real-Time Calculations: Automatic updates provide immediate feedback as adjustments are made.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
  • Flexible and Reusable: Designed for adaptability, enabling multiple uses for in-depth forecasting.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Outlook Therapeutics, Inc. (OTLK).
  • WACC Calculator: A pre-built Weighted Average Cost of Capital sheet with customizable inputs specific to Outlook Therapeutics, Inc. (OTLK).
  • Adjustable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates for Outlook Therapeutics, Inc. (OTLK).
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Outlook Therapeutics, Inc. (OTLK).
  • Interactive Dashboard and Charts: Visual summaries of key valuation metrics for Outlook Therapeutics, Inc. (OTLK) for straightforward analysis.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review Outlook Therapeutics' pre-filled financial data and projections.
  3. Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model update in real-time as you modify assumptions.
  5. Step 5: Evaluate the outputs and utilize the results for investment decisions regarding Outlook Therapeutics, Inc. (OTLK).

Why Choose This Calculator for Outlook Therapeutics, Inc. (OTLK)?

  • Accurate Data: Up-to-date financials from Outlook Therapeutics ensure dependable valuation outcomes.
  • Customizable: Tailor key inputs like growth rates, WACC, and tax rates to align with your forecasts.
  • Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
  • User-Friendly: Simple design and clear instructions make it accessible for all users.

Who Should Use This Product?

  • Investors: Evaluate Outlook Therapeutics’ valuation before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation assessments and validate financial forecasts.
  • Startup Founders: Discover how biotechnology companies like Outlook Therapeutics are valued.
  • Consultants: Create comprehensive valuation reports for client presentations.
  • Students and Educators: Utilize current data to learn and teach valuation methodologies.

What the Template Contains

  • Preloaded OTLK Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.